SLC39A12

Summary

SLC39A12 (solute carrier family 39 member 12, HGNC:20860) is a protein-coding gene on chromosome 10p12.33, encoding Zinc transporter ZIP12 (Q504Y0). Uniporter that promotes Zn(2+) import from the extracellular space to the cytoplasm across the cell membrane.

Zinc is an essential cofactor for hundreds of enzymes. It is involved in protein, nucleic acid, carbohydrate, and lipid metabolism, as well as in the control of gene transcription, growth, development, and differentiation. SLC39A12 belongs to a subfamily of proteins that show structural characteristics of zinc transporters (Taylor and Nicholson, 2003 [PubMed 12659941]).

Source: NCBI Gene 221074 — RefSeq curated summary.

At a glance

• Gene–disease (curated): retinitis pigmentosa (Limited, GenCC)
• GWAS associations: 8
• Clinical variants (ClinVar): 102 total
• MANE Select transcript: NM_001145195

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20860
Approved symbol	SLC39A12
Name	solute carrier family 39 member 12
Location	10p12.33
Locus type	gene with protein product
Status	Approved
Aliases	FLJ30499, ZIP12
Ensembl gene	ENSG00000148482
Ensembl biotype	protein_coding
OMIM	608734
Entrez	221074

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000377369, ENST00000377371, ENST00000377374, ENST00000539911, ENST00000968699

RefSeq mRNA: 4 — MANE Select: NM_001145195 NM_001145195, NM_001282733, NM_001282734, NM_152725

CCDS: CCDS44362, CCDS60493, CCDS60494, CCDS7124

Canonical transcript exons

ENST00000377369 — 13 exons

Exon	Start	End
ENSE00003843151	18042705	18043285
ENSE00003845986	17951918	17952025
ENSE00003889358	17993181	17993291
ENSE00003889513	17965483	17965690
ENSE00003890019	17991151	17991303
ENSE00003891504	17981312	17981483
ENSE00003891965	18003171	18003358
ENSE00003892540	18000667	18000825
ENSE00003893344	17995656	17995722
ENSE00003894233	17987479	17987651
ENSE00003894810	17977902	17978074
ENSE00003894989	17961581	17961862
ENSE00003895824	17953191	17953537

Expression profiles

Bgee: expression breadth broad, 89 present calls, max score 99.54.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.7676 / max 395.2276, expressed in 111 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
104105	1.2130	93
104109	0.2940	49
104106	0.1269	67
104104	0.0641	32
104108	0.0564	10
104107	0.0090	6
104103	0.0043	1

Top tissues by expression

205 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pigmented layer of retina	UBERON:0001782	99.54	gold quality
secondary oocyte	CL:0000655	89.90	gold quality
cerebellar vermis	UBERON:0004720	89.56	gold quality
lateral globus pallidus	UBERON:0002476	87.56	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.41	gold quality
anterior cingulate cortex	UBERON:0009835	84.07	gold quality
putamen	UBERON:0001874	83.83	gold quality
entorhinal cortex	UBERON:0002728	83.42	gold quality
Brodmann (1909) area 9	UBERON:0013540	83.16	gold quality
amygdala	UBERON:0001876	82.81	gold quality
Ammon’s horn	UBERON:0001954	82.79	gold quality
superior frontal gyrus	UBERON:0002661	82.52	gold quality
temporal lobe	UBERON:0001871	82.35	gold quality
right frontal lobe	UBERON:0002810	82.25	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	81.86	gold quality
oocyte	CL:0000023	81.41	gold quality
postcentral gyrus	UBERON:0002581	81.40	gold quality
cerebral cortex	UBERON:0000956	80.04	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.02	gold quality
frontal cortex	UBERON:0001870	79.93	gold quality
neocortex	UBERON:0001950	79.60	gold quality
nucleus accumbens	UBERON:0001882	79.57	gold quality
caudate nucleus	UBERON:0001873	78.75	gold quality
substantia nigra	UBERON:0002038	78.71	gold quality
prefrontal cortex	UBERON:0000451	78.68	gold quality
parietal lobe	UBERON:0001872	78.51	gold quality
corpus callosum	UBERON:0002336	77.75	gold quality
forebrain	UBERON:0001890	77.68	gold quality
primary visual cortex	UBERON:0002436	77.63	gold quality
midbrain	UBERON:0001891	76.72	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	15.41
E-GEOD-84465	yes	11.44
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

43 targeting SLC39A12, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-8080	99.82	67.52	1342
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-586	99.65	70.40	2051
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-7844-5P	99.55	68.56	1428
HSA-MIR-106A-3P	99.53	67.58	995
HSA-MIR-543	99.52	69.03	2595
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-217-5P	99.49	69.93	1419
HSA-MIR-20A-3P	99.44	69.10	1575

Literature-anchored findings (GeneRIF, showing 3)

• Examination of the zinc transporter gene, SLC39A12. (PMID:16311021)
• Data indicate that the zinc transporter ZIP12 (slc39a12) is highly expressed in brain. (PMID:23716681)
• Role of zinc transporter ZIP12 in susceptibility-weighted brain magnetic resonance imaging (MRI) phenotypes and mitochondrial function. (PMID:32716562)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Slc39a12	ENSMUSG00000036949
rattus_norvegicus	Slc39a12	ENSRNOG00000025639
drosophila_melanogaster	Zip71B	FBGN0036461
caenorhabditis_elegans		WBGENE00021936

Paralogs (6): SLC39A14 (ENSG00000104635), SLC39A8 (ENSG00000138821), SLC39A5 (ENSG00000139540), SLC39A6 (ENSG00000141424), SLC39A4 (ENSG00000147804), SLC39A10 (ENSG00000196950)

Protein

Protein identifiers

Zinc transporter ZIP12 — Q504Y0 (reviewed: Q504Y0)

Alternative names: LIV-1 subfamily of ZIP zinc transporter 8, Solute carrier family 39 member 12, Zrt- and Irt-like protein 12

All UniProt accessions (1): Q504Y0

UniProt curated annotations — full annotation on UniProt →

Function. Uniporter that promotes Zn(2+) import from the extracellular space to the cytoplasm across the cell membrane. The transport activity is temperature dependent. May play a role in neurulation and neurite extension. May play a key role in maintaining intracellular zinc content at levels that reduce the inhibitory effects of rises in oxidative stress on spermatogonia and spermatozoa viability during spermatogenesis.

Subcellular location. Membrane.

Tissue specificity. Expressed in brain and eye.

Similarity. Belongs to the ZIP transporter (TC 2.A.5) family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q504Y0-1	1	yes
Q504Y0-2	2
Q504Y0-3	3
Q504Y0-4	4
Q504Y0-5	5

RefSeq proteins (4): NP_001138667, NP_001269662, NP_001269663, NP_689938 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003689	ZIP	Family
IPR041137	ZIP4_N	Domain
IPR049406	ZIP4_12_EF-hand	Domain
IPR050799	ZIP_Transporter	Family

Pfam: PF02535, PF18292, PF21116

Catalyzed reactions (Rhea), 1 shown:

• Zn(2+)(in) = Zn(2+)(out) (RHEA:29351)

UniProt features (32 total): topological domain 9, transmembrane region 8, splice variant 5, sequence variant 5, sequence conflict 3, chain 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q504Y0-F1	69.45	0.14

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 133 (showing top): GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_REGULATION_OF_MICROTUBULE_BASED_PROCESS, GOBP_NEURON_PROJECTION_EXTENSION, GOBP_TRANSITION_METAL_ION_TRANSPORT, GOBP_GROWTH, GOBP_NEUROGENESIS, GOBP_NEURAL_TUBE_DEVELOPMENT, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_MORPHOGENESIS_OF_EMBRYONIC_EPITHELIUM, EFC_Q6, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION

GO Biological Process (12): neural tube formation (GO:0001841), signal transduction (GO:0007165), regulation of neuron projection development (GO:0010975), intracellular monoatomic cation homeostasis (GO:0030003), regulation of microtubule polymerization (GO:0031113), zinc ion import across plasma membrane (GO:0071578), neuron projection extension (GO:1990138), monoatomic ion transport (GO:0006811), zinc ion transport (GO:0006829), bicarbonate transport (GO:0015701), metal ion transport (GO:0030001), transmembrane transport (GO:0055085)

GO Molecular Function (3): zinc ion transmembrane transporter activity (GO:0005385), monoatomic cation:bicarbonate symporter activity (GO:0140410), metal ion transmembrane transporter activity (GO:0046873)

GO Cellular Component (4): plasma membrane (GO:0005886), perinuclear region of cytoplasm (GO:0048471), extracellular vesicle (GO:1903561), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transport	3
cellular process	2
zinc ion transmembrane transport	2
cellular anatomical structure	2
embryonic epithelial tube formation	1
neural tube development	1
cell communication	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
neuron projection development	1
regulation of plasma membrane bounded cell projection organization	1
intracellular monoatomic ion homeostasis	1
monoatomic cation homeostasis	1
regulation of microtubule polymerization or depolymerization	1
regulation of protein polymerization	1
microtubule polymerization	1
regulation of supramolecular fiber organization	1
inorganic cation import across plasma membrane	1
developmental cell growth	1
neuron projection morphogenesis	1
developmental growth involved in morphogenesis	1
transition metal ion transport	1
monoatomic cation transport	1
transition metal ion transmembrane transporter activity	1
bicarbonate transmembrane transporter activity	1
solute:monoatomic cation symporter activity	1
monoatomic cation transmembrane transporter activity	1
metal ion transport	1
membrane	1
cell periphery	1
cytoplasm	1
extracellular region	1
vesicle	1
extracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1280 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC39A12	SLC39A11	Q8N1S5	775
SLC39A12	SLC39A1	Q9NY26	736
SLC39A12	SLC30A2	Q9BRI3	735
SLC39A12	SLC30A6	Q6NXT4	715
SLC39A12	SLC39A2	Q9NP94	697
SLC39A12	SLC30A9	Q6PML9	681
SLC39A12	SLC30A7	Q8NEW0	658
SLC39A12	SLC30A4	O14863	656
SLC39A12	SLC30A3	Q99726	655
SLC39A12	SLC30A1	Q9Y6M5	653
SLC39A12	SLC39A3	Q9BRY0	650
SLC39A12	SLC30A5	Q8TAD4	644
SLC39A12	SLC30A10	Q6XR72	612
SLC39A12	SLC39A9	Q9NUM3	538
SLC39A12	SLC30A8	Q8IWU4	521

IntAct

4 interactions, top by confidence:

A	B	Type	Score
SLC39A12		psi-mi:“MI:0914”(association)	0.350
SLC39A12	GPR39	psi-mi:“MI:0914”(association)	0.350
SLC39A12	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (318): FXYD6 (Affinity Capture-MS), PODXL2 (Affinity Capture-MS), SELT (Affinity Capture-MS), LETMD1 (Affinity Capture-MS), GJC1 (Affinity Capture-MS), TLCD1 (Affinity Capture-MS), GOLM1 (Affinity Capture-MS), SLC35B2 (Affinity Capture-MS), HSD17B7 (Affinity Capture-MS), SQLE (Affinity Capture-MS), GJA1 (Affinity Capture-MS), ZFPL1 (Affinity Capture-MS), CUX1 (Affinity Capture-MS), ABHD12 (Affinity Capture-MS), ABHD14A (Affinity Capture-MS)

ESM2 similar proteins: A0A0G2KQY6, A0A6I8PMZ8, A0JPN2, A4IGY6, A5D7L5, A7T1N0, B3DHU2, O43868, O75899, O88871, O94402, P04919, P0DX17, P23562, P26432, P26433, P48764, P55205, Q08E40, Q0DHJ5, Q0DWA9, Q0VCH8, Q15043, Q28C60, Q4VAE3, Q504Y0, Q5FVQ0, Q5FWH7, Q5RAB7, Q5Z413, Q6DCK1, Q6L8F3, Q6PI78, Q75N73, Q78IQ7, Q80T41, Q8K596, Q8VIH3, Q8W469, Q91W10

Diamond homologs: A0A0G2KQY6, A0A6I8PMZ8, A4IGY6, A5D7H1, A5D7L5, A8WMY3, A8X482, L5KLU7, P0DX17, Q06916, Q15043, Q1KZG0, Q29175, Q2M1K6, Q31125, Q504Y0, Q5FVQ0, Q5FWH7, Q5R6I6, Q5RAB7, Q5RFD5, Q5TJF6, Q6L8F3, Q6MGB4, Q6P5F6, Q6PEH9, Q75N73, Q78IQ7, Q8AW42, Q8BZH0, Q91W10, Q92504, Q96H72, Q9C0K1, Q9M647, Q9PUB8, Q9ULF5, Q9UT11, Q9V3A4, Q9XTQ7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

102 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	88
Likely benign	6
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1997 predictions. Top by Δscore:

Variant	Effect	Δscore
10:17952026:G:GA	donor_loss	1.0000
10:17961580:GT:G	acceptor_gain	1.0000
10:17961695:G:GT	donor_gain	1.0000
10:17965482:GT:G	acceptor_gain	1.0000
10:17981479:GGAGA:G	donor_gain	1.0000
10:17981480:GAGA:G	donor_gain	1.0000
10:17981480:GAGAG:G	donor_gain	1.0000
10:17981481:A:T	donor_gain	1.0000
10:17981482:GA:G	donor_gain	1.0000
10:17981484:G:GG	donor_gain	1.0000
10:18000656:T:TA	acceptor_gain	1.0000
10:18000823:TGGG:T	donor_loss	1.0000
10:18000824:GG:G	donor_gain	1.0000
10:18000825:GG:G	donor_gain	1.0000
10:18000825:GGTA:G	donor_loss	1.0000
10:18000826:G:GC	donor_loss	1.0000
10:18000826:G:GG	donor_gain	1.0000
10:18000827:TAAG:T	donor_loss	1.0000
10:18003162:A:AG	acceptor_gain	1.0000
10:18003163:A:AG	acceptor_gain	1.0000
10:18003164:A:AG	acceptor_gain	1.0000
10:18003165:C:G	acceptor_gain	1.0000
10:18003167:TCA:T	acceptor_loss	1.0000
10:18003169:A:AG	acceptor_gain	1.0000
10:18003169:AG:A	acceptor_gain	1.0000
10:18003170:G:GC	acceptor_gain	1.0000
10:18003170:GG:G	acceptor_gain	1.0000
10:18003170:GGA:G	acceptor_gain	1.0000
10:18003170:GGAGA:G	acceptor_gain	1.0000
10:18003328:G:T	donor_gain	1.0000

AlphaMissense

4550 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:18003236:A:C	S609R	0.995
10:18003238:C:A	S609R	0.995
10:18003238:C:G	S609R	0.995
10:18000753:T:C	F563L	0.991
10:18000755:C:A	F563L	0.991
10:18000755:C:G	F563L	0.991
10:18000711:A:C	S549R	0.990
10:18000713:C:A	S549R	0.990
10:18000713:C:G	S549R	0.990
10:17987490:A:C	S370R	0.989
10:17987492:C:A	S370R	0.989
10:17987492:C:G	S370R	0.989
10:18000736:T:C	L557P	0.989
10:18003332:T:C	F641L	0.989
10:18003334:C:A	F641L	0.989
10:18003334:C:G	F641L	0.989
10:18042783:T:A	W676R	0.989
10:18042783:T:C	W676R	0.989
10:17981396:A:C	S337R	0.987
10:17981398:T:A	S337R	0.987
10:17981398:T:G	S337R	0.987
10:18000733:G:A	G556D	0.986
10:17987610:G:T	G410W	0.983
10:18003257:G:A	G616R	0.982
10:18003257:G:C	G616R	0.982
10:17987610:G:A	G410R	0.981
10:17987610:G:C	G410R	0.981
10:18000801:T:C	C579R	0.981
10:18003174:A:C	D588A	0.980
10:17987611:G:A	G410E	0.978

dbSNP variants (sampled 300 via entrez): RS1000028503 (10:17975990 C>A,G,T), RS1000032683 (10:17977077 A>G), RS1000037821 (10:18013051 A>G), RS1000059985 (10:17983007 A>G), RS1000146801 (10:18043152 G>A,T), RS1000159365 (10:18025525 T>C), RS1000182930 (10:17992153 C>T), RS1000190286 (10:17952597 T>G), RS1000258465 (10:17982912 C>T), RS1000304815 (10:18038827 T>C), RS1000311718 (10:18020214 G>A,T), RS1000321842 (10:17971154 T>C), RS1000408466 (10:18030325 C>A), RS1000410256 (10:18020339 G>A,C,T), RS1000435934 (10:17988049 G>A)

Disease associations

OMIM: gene MIM:608734 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
retinitis pigmentosa	Limited	Autosomal recessive

Mondo (1): retinitis pigmentosa (MONDO:0019200)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST003996_25	Monobrow	4.000000e-09
GCST005999_25	Aspartate aminotransferase levels	2.000000e-19
GCST006257_3	Elevated fasting plasma glucose	8.000000e-07
GCST010146_32	Serum immune biomarker levels	2.000000e-18
GCST90002393_325	Monocyte count	3.000000e-09
GCST90002398_169	Neutrophil count	1.000000e-12
GCST90002407_88	White blood cell count	3.000000e-13
GCST90011899_166	Aspartate aminotransferase levels	4.000000e-159

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0007906	synophrys measurement
EFO:0004736	aspartate aminotransferase measurement
EFO:0004869	YKL40 measurement
EFO:0004872	inflammatory biomarker measurement
EFO:0005091	monocyte count
EFO:0004833	neutrophil count

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D012174	Retinitis Pigmentosa	C11.270.684; C11.768.585.658.500; C16.320.290.684

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC39 family of metal ion transporters

CTD chemical–gene interactions

4 total (human), top 4 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
CGP 52608	affects binding, increases reaction	1
Benzo(a)pyrene	increases methylation, decreases methylation	1
Zinc	increases transport	1
Antirheumatic Agents	decreases expression	1

Clinical trials (associated diseases)

234 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00000114	PHASE3	COMPLETED	Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
NCT00000116	PHASE3	COMPLETED	Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
NCT00346333	PHASE3	COMPLETED	Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A
NCT01786395	PHASE3	TERMINATED	Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa
NCT04224207	PHASE3	COMPLETED	Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton’s Jelly Derived Mesenchymal Stem Cells
NCT04636853	PHASE3	COMPLETED	CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
NCT05537220	PHASE3	ACTIVE_NOT_RECRUITING	Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05800301	PHASE3	COMPLETED	Management of Retinitis Pigmentosa Via Combination of Wharton’s Jelly-derived Mesenchymal Stem Cells and Magnovision
NCT05926583	PHASE3	ACTIVE_NOT_RECRUITING	A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
NCT06388200	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT07082855	PHASE3	NOT_YET_RECRUITING	A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa
NCT07290530	PHASE3	NOT_YET_RECRUITING	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT00100230	PHASE2	COMPLETED	DHA and X-Linked Retinitis Pigmentosa
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT00447993	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
NCT01233609	PHASE2	COMPLETED	Trial of Oral Valproic Acid for Retinitis Pigmentosa
NCT01399515	PHASE2	COMPLETED	Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01560715	PHASE2	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
NCT02609165	PHASE2	COMPLETED	Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
NCT02661711	PHASE2	COMPLETED	Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
NCT02804360	PHASE2	UNKNOWN	Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study
NCT02837640	PHASE2	UNKNOWN	Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT03073733	PHASE2	COMPLETED	Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa
NCT04068207	PHASE2	COMPLETED	Minocycline Treatment in Retinitis Pigmentosa
NCT04356716	PHASE2	COMPLETED	Sildenafil for Treatment of Choroidal Ischemia
NCT04604899	PHASE2	COMPLETED	Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa
NCT04763369	PHASE2	UNKNOWN	Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP)
NCT04864496	PHASE2	UNKNOWN	Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
NCT04945772	PHASE2	COMPLETED	Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT05085964	PHASE2	TERMINATED	An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
NCT05392179	PHASE2	COMPLETED	A Study in Subjects With Retinitis Pigmentosa
NCT06627179	PHASE2	RECRUITING	Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06628947	PHASE2	RECRUITING	A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
NCT06912633	PHASE2	RECRUITING	Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
NCT00063765	PHASE1	COMPLETED	Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye
NCT00065455	PHASE1	COMPLETED	Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
NCT00458575	PHASE1	TERMINATED	A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa
NCT01068561	PHASE1	COMPLETED	Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa